People still believe that hyperbaric oxygen therapy only works at higher pressures. Most of them are only practicing with higher pressure protocols and have not taken the time to go through the steady influx of all the recent data and research making its way into current medical journals and publications. If they did, they would very quickly be able to see that lower pressures can provide very powerful effects, and sometimes even more powerful than those observed with higher pressures; the latter was just the case in a landmark study released in 2013. This study was published in the UHMS journal (a mainstream, peer reviewed, hyperbaric medical journal) and looked at the difference between 2.4 ATA (higher pressure HBOT) and 1.5 ATA (lower pressure HBOT). The results were stunning in virtually all areas observed. Researchers observed 92 inflammatory genes and this is what they quoted:

"Interestingly, oxygen at 1.5 atm abs affected many genes much more strongly than oxygen at 2.4. The reasons for this effect are unknown, but it does raise questions about the most appropriate treatment pressures for inflammatory conditions"

It was landmark study for lower pressure protocols, because it clearly demonstrated that the lower pressure protocols (1.5 ATA) had much stronger effects in the inflammatory genes observed than the higher pressures (2.4 ATA). <view study>     Read Less

This study looked at physiological changes that  occurred in the brain with the application of hyperbaric therapy following traumatic brain injury. They noticed an improvement in the blood-brain barrier, a reduction in inflammation and inflammatory proteins, a reduction in both swelling and the size of the damage, and more importantly an improvement in neurological status including motor and cognitive function <view study> Read Less

Following spinal cord injuries, hyperbaric oxygen therapy (HBOT) has been shown to produce a positive effect on healing, but it still remains unclear of the main mechanisms of action. This study followed spinal cord injuries treated with HBOT and demonstrated that this group had higher and longer expressions of VEGF (Vascular endothelial growth factor), which is responsible for the growth of new blood vessels. This follows many other studies and citations, particularly with non-healing wounds, where HBOT facilitates the body to produce more blood vessels to damaged tissue, for long terms benefits <view study> Read Less

This study published in the Journal of Pain, recognizes past clinical data for the use of hyperbaric oxygen therapy (HBOT) in models of pain. Here they looked at daily application of hyperbaric oxygen for 1 week and evaluated physiological changes that may explain the analgesic effects of hyperbaric therapy. The results showed a reduction in numerous inflammatory markers, along with pain relief. By understanding the mechanism, HBOT may get more wide use for being a safe and effective way to reduce inflammatory pain <view study> Read Less

Hyperbaric oxygen therapy is widely used as an effective off-label use for stroke victims. Research has found that this therapy not only targets oxygenation of the effected area and reduces inflammation, but also has been shown to promote bone marrow stem cells (BMSCs) to proliferate and mobilize, which essentially becomes an important part of the neurogenic (nervous system growth) effects that have been demonstrated from hyperbaric procedures. Mobilization of these BMSCs to the damaged areas were more improved in long course hyperbaric treatments, suggesting the duration of therapy is crucial for promoting their neurogenic effects.

It is important to also note that emerging stem cell research has clearly demonstrated that BMSCs secrete brain-derived neurotrophic factor (BDNF) and the addition of anti-BDNF neutralising antibodies to MSC-conditioned medium attenuated its neuroprotective effect <view study>

This study also looked at the release of BDNF and found that a 3 week course of HBOT was able to produce significantly higher levels of BDNF and GDNF, than shorter 2 day course of HBO. These results indicated that longer and repetitive HBO therapy promoted more neurotrophic factor production, including BDNF and GDNF. <view study> Read Less